|
|
Article: Study Demonstrates New FORTOVASE(R) Dosing Strategy Maintains Low Viral Load While Reducing Triglycerides and Cholesterol; - Two Additional Studies Look at Saquinavir Exposure Levels With INVIRASE(R) or FORTOVASE With Mini-Dose Ritonavir -.
- Article from:
- PR Newswire
- Article date:
- April 22, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NUTLEY, N.J. -- Roche today announced clinical study results indicating that HIV patients who modified their twice-daily protease inhibitor regimen of FORTOVASE(R) (saquinavir soft gel capsules) with ritonavir (FORTOVASE/r) by increasing the FORTOVASE dose and minimizing the ritonavir dose were able to maintain viral suppression below 400 copies/mL with substantial reductions in triglycerides and cholesterol. A second study found similar saquinavir exposure levels among patients taking INVIRASE(R) (saquinavir mesylate) with ritonavir (INVIRASE/r) or FORTOVASE/r, when given at the same dose either once- or twice-daily. These data were presented at the 3rd International ...